Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Xencor Inc (XNCR)

  • Company Report
  • Feb. 27, 2023, 14:25 UTC
  • 58

New Form 10-K for Xencor Inc

Comment Full text

MAIA Biotechnology Inc. (MAIA)

  • Company Report
  • Feb. 26, 2023, 16:46 UTC
  • 60

What We Fight at MAIA - Small Cell Lung Cancer

Comment Full text

Prothena Corporation plc (PRTA)

  • Company Report
  • Feb. 24, 2023, 01:35 UTC
  • 57

Prothena Corporation plc - Fourth Quarter 2022

Comment Full text

Dynavax Technologies Corporation (DVAX)

  • Company Report
  • Feb. 24, 2023, 00:55 UTC
  • 56

New Form 10-K for Dynavax Technologies Corporation

Comment Full text

MannKind Corporation (MNKD)

  • Company Report
  • Feb. 24, 2023, 00:54 UTC
  • 60

New Form 10-K for MannKind Corporation

Comment Full text

Guardant Health Inc (GH)

  • Company Report
  • Feb. 24, 2023, 00:10 UTC
  • 58

Guardant Health, Inc. - Fourth Quarter 2022

Comment Full text

Luna Innovations Incorporated (LUNA)

  • Company Report
  • Feb. 23, 2023, 16:34 UTC
  • 59

Luna Innovations Partners to Deliver Clean Energy from Largest Offshore Wind Project in the U.S.

Comment Full text

Baudax Bio Inc. (BXRX)

  • Company Report
  • Feb. 23, 2023, 16:05 UTC
  • 59

New SEC Form for Baudax Bio, Inc.

Comment Full text

Edgewise Therapeutics Inc (EWTX)

  • Company Report
  • Feb. 23, 2023, 16:05 UTC
  • 61

Edgewise Therapeutics - Fourth Quarter 2022

Comment Full text

Vericel Corporation (VCEL)

  • Company Report
  • Feb. 23, 2023, 16:00 UTC
  • 58

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

Comment Full text
  • Previous
  • 26
  • 27
  • 28
  • 29
  • 30
  • Next

Search

News categories

  • Technical Exchange News(9676)
  • Event(407)
  • SEC News(159033)
  • FDA Approval(9138)
  • Company Report(721)
  • Business News(108143)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin